Osterweis Capital Management’s Biogen BIIB Stock Holding History

Osterweis Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7	Closed	-$2K	–	237
2022 Q3	$2K	Buy	+7	New	+$1.49K	﹤0.01%	227

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Osterweis Capital Management's BIIB Position: Q4 2022 in Review

Osterweis Capital Management sold out of Biogen (BIIB) in Q4 2022, closing a stake of 7 shares — an estimated $2K sold.

Osterweis Capital Management first reported a position in BIIB in Q3 2022 and held it in 1 quarter. The position peaked at $2K in Q3 2022. 1,031 funds tracked by Wall St. Rank hold BIIB as of Q4 2022.

Osterweis Capital Management reported no remaining Biogen position as of Q4 2022 after selling out during the quarter.
Osterweis Capital Management sold 7 Biogen shares in Q4 2022, an estimated $2K.
Osterweis Capital Management first reported a position in Biogen in Q3 2022 and held it in 1 quarter.
Osterweis Capital Management's Biogen position peaked at $2K in Q3 2022.
1,031 funds tracked by Wall St. Rank held Biogen as of Q4 2022.

Based on Osterweis Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.